Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Correction: A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.

Liu S, Kumari S, Hu Q, Senapati D, Venkadakrishnan VB, Wang D, DePriest AD, Schlanger SE, Ben-Salem S, Valenzuela MM, Willard B, Mudambi S, Swetzig WM, Das GM, Shourideh M, Koochekpour S, Falzarano SM, Magi-Galluzzi C, Yadav N, Chen X, Lao C, Wang J, Billaud JN, Heemers HV.

Elife. 2017 Nov 22;6. pii: e33738. doi: 10.7554/eLife.33738. No abstract available.

2.

A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.

Liu S, Kumari S, Hu Q, Senapati D, Venkadakrishnan VB, Wang D, DePriest AD, Schlanger SE, Ben-Salem S, Valenzuela MM, Willard B, Mudambi S, Swetzig WM, Das GM, Shourideh M, Koochekpour S, Falzarano SM, Magi-Galluzzi C, Yadav N, Chen X, Lao C, Wang J, Billaud JN, Heemers HV.

Elife. 2017 Aug 18;6. pii: e28482. doi: 10.7554/eLife.28482. Erratum in: Elife. 2017 Nov 22;6:.

3.

A 72-Year-Old Man With Obstructive Voiding Symptoms, Elevated Prostate-specific Antigen Level, and Nodular Digital Rectal Examination.

Agrawal S, Klein E, Falzarano SM, Purysko AS.

Urology. 2017 Jun;104:22-24. doi: 10.1016/j.urology.2016.12.008. Epub 2016 Dec 22. No abstract available.

PMID:
28017886
4.

Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.

Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, Febbo PG, Lee M, Lawrence HJ, Klein EA.

Oncotarget. 2016 Jun 7;7(23):33855-65. doi: 10.18632/oncotarget.8944.

5.

Renal Cell Carcinoma Occurring in Patients With Prior Neuroblastoma: A Heterogenous Group of Neoplasms.

Falzarano SM, McKenney JK, Montironi R, Eble JN, Osunkoya AO, Guo J, Zhou S, Xiao H, Dhanasekaran SM, Shukla S, Mehra R, Magi-Galluzzi C.

Am J Surg Pathol. 2016 Jul;40(7):989-97. doi: 10.1097/PAS.0000000000000632.

PMID:
26975037
6.

Novel biomarkers and genomic tests in prostate cancer: a critical analysis.

Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C.

Minerva Urol Nefrol. 2015 Sep;67(3):211-31. Epub 2015 Jun 9. Review.

PMID:
26054411
7.

Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?

Chen DJ, Falzarano SM, McKenney JK, Przybycin CG, Reynolds JP, Roma A, Jones JS, Stephenson A, Klein E, Magi-Galluzzi C.

BJU Int. 2015 Aug;116(2):220-9. doi: 10.1111/bju.12880. Epub 2014 Dec 15.

8.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

9.

ERG protein expression as a biomarker of prostate cancer.

Falzarano SM, Magi-Galluzzi C.

Biomark Med. 2013 Dec;7(6):851-65. doi: 10.2217/bmm.13.105. Review.

PMID:
24266818
10.

Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.

Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C.

BMC Genomics. 2013 Oct 8;14:690. doi: 10.1186/1471-2164-14-690.

11.

Prostate cancer patients older than 70 years treated by radical prostatectomy have higher biochemical recurrence rate than their matched younger counterpart.

Ko J, Falzarano SM, Walker E, Streator Smith K, Stephenson AJ, Klein EA, Magi-Galluzzi C.

Prostate. 2013 Jun;73(8):897-903. doi: 10.1002/pros.22635. Epub 2012 Dec 31.

PMID:
23280623
12.

Metastatic papillary thyroid carcinoma to the kidney: report of two cases mimicking primary renal cell carcinoma and review of the literature.

Falzarano SM, Chute DJ, Magi-Galluzzi C.

Pathology. 2013 Jan;45(1):89-93. doi: 10.1097/PAT.0b013e32835b5dcc. Review. No abstract available.

PMID:
23255036
13.

Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1.

Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, Falzarano SM, Magi-Galluzzi C, Klein EA, Ting AH.

Cancer Res. 2013 Feb 1;73(3):1211-8. doi: 10.1158/0008-5472.CAN-12-3128. Epub 2012 Dec 11.

14.

Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy.

Sinnott M, Falzarano SM, Hernandez AV, Jones JS, Klein EA, Zhou M, Magi-Galluzzi C.

Prostate. 2012 Aug 1;72(11):1179-86. doi: 10.1002/pros.22467. Epub 2011 Dec 7.

PMID:
22161896
15.

ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.

Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H, Magi-Galluzzi C.

Virchows Arch. 2011 Oct;459(4):441-7. doi: 10.1007/s00428-011-1128-4. Epub 2011 Jul 20.

PMID:
21773753
16.

Prostate cancer staging and grading at radical prostatectomy over time.

Falzarano SM, Magi-Galluzzi C.

Adv Anat Pathol. 2011 Mar;18(2):159-64. doi: 10.1097/PAP.0b013e31820cb506. Review.

PMID:
21326013
17.

Single focus prostate cancer: pathological features and ERG fusion status.

Falzarano SM, Zhou M, Hernandez AV, Klein EA, Rubin MA, Magi-Galluzzi C.

J Urol. 2011 Feb;185(2):489-94. doi: 10.1016/j.juro.2010.09.093. Epub 2010 Dec 17.

PMID:
21167530
18.

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.

Mod Pathol. 2010 Nov;23(11):1499-506. doi: 10.1038/modpathol.2010.150. Epub 2010 Aug 6.

19.

Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy.

Falzarano SM, Zhou M, Hernandez AV, Moussa AS, Jones JS, Magi-Galluzzi C.

Urology. 2010 Sep;76(3):682-7. doi: 10.1016/j.urology.2009.11.067. Epub 2010 Mar 5.

PMID:
20206973
20.

Undifferentiated gastric carcinoma with lymphoid stroma (lymphoepithelioma-like carcinoma/medullary carcinoma).

Falzarano SM, Mourmouras V, Mastrogiulio MG, La Magra C, Vindigni C.

Pathologica. 2009 Feb;101(1):15-7.

PMID:
19771767
21.

Elastofibroma dorsi: three cases of personal experience.

Neri A, Caruso S, Bettarini F, Falzarano SM, Di Martino M, Vuolo G, Pedrazzani C, Marrelli D, Roviello F.

G Chir. 2009 Mar;30(3):96-9.

PMID:
19351459
22.

Report of two cases of Rosai-Dorfman disease with only skin involvement.

Mourmouras V, Falzarano SM, Miracco C.

Pathologica. 2008 Oct;100(5):414-5.

PMID:
19253603
23.

Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor.

Zhou M, Reuther AM, Levin HS, Falzarano SM, Kodjoe E, Myles J, Klein E, Magi-Galluzzi C.

Mod Pathol. 2009 Mar;22(3):385-92. doi: 10.1038/modpathol.2008.190. Epub 2008 Nov 28.

24.

Urothelial Carcinoma and its Variants.

Magi-Galluzzi C, Falzarano SM, Zhou M.

Surg Pathol Clin. 2008 Dec;1(1):159-209. doi: 10.1016/j.path.2008.07.004. Epub 2008 Dec 6. Review.

PMID:
26837906
25.

Compound melanocytic nevus associated with dermatofibroma: an additional case.

Mourmouras V, Falzarano SM, Malagnino V, Miracco C.

J Cutan Pathol. 2007 Sep;34(9):736-7. No abstract available.

PMID:
17696924
26.

Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours.

Miracco C, Cosci E, Oliveri G, Luzi P, Pacenti L, Monciatti I, Mannucci S, De Nisi MC, Toscano M, Malagnino V, Falzarano SM, Pirtoli L, Tosi P.

Int J Oncol. 2007 Feb;30(2):429-36.

PMID:
17203225
27.

[Primary cardiac echinococcosis].

Malagnino V, Falzarano SM.

Pathologica. 2006 Aug;98(4):232-4. Italian.

PMID:
17175792

Supplemental Content

Loading ...
Support Center